MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/antibiotics15060531

Медицинская библиотека · Antibiotics (Basel, Switzerland) · 2026

Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg).

Bordin Dmitry S, Andreev Dmitrii N, Abdulkhakov Sayar R, Voynovan Irina N, Bakulin Igor G, Bakulina Natalia V, Vologzhanina Ludmila G, Starostin Boris D, Sarsenbayeva Aiman S, Ilchishina Tatyana A, Tarasova Larisa V, Kononova Alla G, Alekseenko Sergey A, Zaytsev Oleg V, Dekhnich Natalya N, Bogomolov Pavel O, Tarasova Galina N, Kolokolnikova Olga A, Khlynov Igor B, Plotnikova Ekaterina Yu, Baryshnikova Natalia V, Livzan Maria A, Osipenko Marina F, Bakanova Natalya V, Partsvania-Vinogradova Ekaterina V, Chebotareva Margarita V, Abdulkhakov Rustam A, Savilova Inna V, Sushilova Anastasia G, Kolbasnikov Sergey V, Khurmatullina Alsu R, Maev Igor V, Tishchenko Maria O, Petrova Rimma E, Morkovkina Ludmila V, Tsyganova Yulia V, Kozlova Margarita D, Iakovlev Aleksei A, Volkov Alexander S, Moroz Elizaveta S, Gaus Olga V, Alba Singla, Farrés Oriol, Moreira Leticia, Parra Pablo, Nyssen Olga P, Megraud Francis, O'Morain Colm, Gisbert Javier P

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/

OBJECTIVE

Eradication of Helicobacter pylori typically uses acid-suppressing agents plus antimicrobials, but treatment failure may reach 20-30%. Adjunctive rebamipide has been proposed as a strategy to improve treatment outcomes. This study aimed to assess the effectiveness and safety of first-line empirical therapy when rebamipide was added to eradication regimens.

METHODS

Treatment-naïve patient data were collected between January 2020 and August 2024 from the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, prospective, multicentre, observational study. Rebamipide-containing regimens were analysed and compared with those without rebamipide. Effectiveness was assessed using a modified intention-to-treat approach.

RESULTS

Overall, 4581 patients (mean age 48 ± 15 years, 64% women) from 15 Russian cities were included. From those, 820 patients received eradication therapy with rebamipide and 3761 without rebamipide. Overall effectiveness was significantly higher with rebamipide (731/763, 96%) than without it (2785/3059, 91%) (p = 0.0002). Rebamipide-containing triple therapy consisting of a proton-pump inhibitor (PPI), clarithromycin and amoxicillin was associated with effectiveness above 90%, while rebamipide-containing quadruple therapy consisting of a PPI, clarithromycin, amoxicillin and bismuth yielded a 97% eradication rate, compared with 79% and 95%, respectively, without rebamipide (p < 0.001). Adverse events were significantly more frequent in patients receiving rebamipide-containing regimens (46% vs. 29%, p < 0.0001), though none were serious or caused discontinuation. Compliance was similar in both groups (99% vs. 98.5%; p > 0.05).

CONCLUSIONS

In this observational registry cohort, first-line empirical triple therapy with amoxicillin-clarithromycin, and quadruple therapy with amoxicillin-clarithromycin-bismuth, both prescribed with rebamipide, were associated with higher eradication rates than regimens without rebamipide.

Для цитирования: Bordin Dmitry S, Andreev Dmitrii N, Abdulkhakov Sayar R, Voynovan Irina N, Bakulin Igor G, Bakulina Natalia V, Vologzhanina Ludmila G, Starostin Boris D, Sarsenbayeva Aiman S, Ilchishina Tatyana A, Tarasova Larisa V, Kononova Alla G, Alekseenko Sergey A, Zaytsev Oleg V, Dekhnich Natalya N, Bogomolov Pavel O, Tarasova Galina N, Kolokolnikova Olga A, Khlynov Igor B, Plotnikova Ekaterina Yu, Baryshnikova Natalia V, Livzan Maria A, Osipenko Marina F, Bakanova Natalya V, Partsvania-Vinogradova Ekaterina V, Chebotareva Margarita V, Abdulkhakov Rustam A, Savilova Inna V, Sushilova Anastasia G, Kolbasnikov Sergey V, Khurmatullina Alsu R, Maev Igor V, Tishchenko Maria O, Petrova Rimma E, Morkovkina Ludmila V, Tsyganova Yulia V, Kozlova Margarita D, Iakovlev Aleksei A, Volkov Alexander S, Moroz Elizaveta S, Gaus Olga V, Alba Singla, Farrés Oriol, Moreira Leticia, Parra Pablo, Nyssen Olga P, Megraud Francis, O'Morain Colm, Gisbert Javier P. Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg).. Antibiotics (Basel, Switzerland). 2026. DOI: 10.3390/antibiotics15060531.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.